Clinical Variant Analysis: Part III

· Andreas Scherer · Best Practices in Genetic Analysis, VSClinical

Clinical Variant Analysis – Classification Criteria of Benign Variants

The classification of benign variants is overall simpler and more straightforward, with the majority of benign variants being eliminated through allele frequency in various population catalogs.

BA1 If a variant is common in one or more population catalog, as indicated by the allele frequency associated by the appropriate sub-population, it can be assumed to be benign. While the ACMG guidelines recommend an allele frequency threshold of 5%, other authors have found that a much lower threshold is more appropriate. For instance, Nykamp et al. (5) found that 97.3% of pathogenic variants had allele frequencies of less than 0.01%. They recommend a threshold of 0.5% for dominant genes and a threshold of 1% for recessive genes.

BS1 If a variant’s allele frequency does not meet the threshold for BA1, but its frequency is still greater than expected for the observed disorder, then BS1 should be applied. Kelly et al. (14) found that a threshold of 0.02% was sufficient for this criterion.

BS2 This criterion is applied if the disease is fully penetrant at an early age and the mutation is observed in a well-documented healthy adult for a dominant (heterozygous), recessive (homozygous), or X-linked (hemizygous) condition.

BS3 Well-established in vitro or in vivo functional studies showing that a variant has no damaging effect on protein function or splicing are considered strong evidence for a benign classification.

BS4 Lack of segregation of a variant with a disease is strong evidence for a benign classification. However, careful evaluation is necessary to rule out the occurrence of the disease in self-reported, unaffected individuals who may have mild symptoms of the disorder. As with PS2, the ACMG guidelines recommend confirmation of family relationships.

BP1 In genes for which LoF variants are the only known mechanism of pathogenicity, missense variants are be considered supporting evidence for a benign classification.

To continue reading the classification criteria of pathogenic variants, please download a complimentary copy of “Clinical Variant Analysis” by clicking on the button below.

Leave a comment

Andreas Scherer

About Andreas Scherer

Dr. Andreas Scherer is CEO of Golden Helix. The company has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over a decade. Its innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from next-generation sequencing. With its solutions, hundreds of the world’s hospitals and testing labs are able to harness the full potential of genomics to identify the cause of disease, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in thousands of peer-reviewed publications. Golden Helix is also on the Inc 5000 list of the fastest-growing private companies in the US. He is also Managing Partner of Salto Partners, Inc, a management consulting firm headquartered in Nevada.  He has extensive experience successfully managing growth as well as orchestrating complex turnaround situations. His company, Salto Partners, advises on business strategy, financing, sales, and operations. Clients are operating in the high-tech and life sciences space. Dr. Scherer holds a Ph.D. in computer science from the University of Hagen, Germany, and a Master of Computer Science from the University of Dortmund, Germany. He is author and co- author of over 20 international publications and has written books on project management, the Internet, and artificial intelligence. His latest book, “Be Fast Or Be Gone”, is a prizewinner in the 2012 Eric Hoffer Book Awards competition, and has been named a finalist in the 2012 Next Generation Indie Book Awards! 

View all posts by Andreas Scherer →